Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results - 16/04/13
, Barış Yımaz a, Fuat Ekiz a, Zeynep Giniş b, Akif Altınbaş a, Bora Aktaş a, Yaşar Tuna c, Şahin Çoban a, Namık Delibaş b, Osman Yüksel a
Corresponding author. Karargahtepe mahallesi, Çamaltı sokak, 141/3, 06120, Keçiören, Ankara, Turkey. Tel.: +90 312 596 29 11; fax: +90 312 318 66 90.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and aim |
The aim of this study was to assess and compare the performance of a series of non-invasive tests to detect fibrosis in patients with chronic hepatitis B (CHB).
Patients and methods |
Seventy-six patients with CHB, whose blood samples were collected and biopsies were done on the same day, were included in this study. Pre-treatment calculations of aspartate aminotransferase to platelet ratio index (APRI), Forn’s index, FIB-4, S-index, Shanghai Liver Fibrosis Group’s index (SLFG) and Hepascore® were done and relations with mild and advanced fibrosis and cirrhosis were assessed. Post-treatment values of APRI, Forn’s index, FIB-4, S-index with oral antiviral agents were also investigated.
Results |
APRI, S-index, SLFG, FIB-4, Forn’s index and Hepascore® had 0.669, 0.669, 0.739, 0.741, 0.753, 0.780; retrospectively Area Under the Receiver Operating Characteristic Curve (AUROC) for significant fibrosis. APRI, Forn’s index, S-index, FIB-4, SLFG, and Hepascore® had 0.681, 0.714, 0.715, 0.738, 0.747, 0.777 retrospectively AUROC for advanced fibrosis. APRI, SLFG, FIB-4, Forn’s index, S-index, and Hepascore® had 0.741, 0.742, 0.768, 0.779, 0.792, 0.824 retrospectively AUROC for cirrhosis. APRI, Forn’s index, FIB-4 and S-index were significantly lower in post-treatment group compared with pre-treatment group (P-values: <0.05, 0.001, 0.003, 0.018; respectively).
Conclusion |
Hepascore® showed the best performance to predict significant fibrosis. Our study also suggests that the use of non-invasive test to predict fibrosis in patients with CHB may reduce the need for liver biopsy and may help to monitor the efficacy of treatment.
Le texte complet de cet article est disponible en PDF.Plan
Vol 37 - N° 2
P. 152-158 - avril 2013 Retour au numéro
Article précédent
- Immunohistochemical profile of ezrin and radixin in human liver epithelia during fetal development and pediatric cholestatic diseases
- Audrey Clapéron, Dominique Debray, Marie-José Redon, Martine Mergey, Thanh Huong Nguyen Ho-Bouldoires, Chantal Housset, Monique Fabre, Laura Fouassier
- Intraductal thermal injury using a heat probe and radiofrequency ablation electrode in a swine model of biliary stenosis
- Jae Uk Shin, Kwang Hyuck Lee, Su-A Kim, Jong Hak Choi, Kwang Min Kim, Jong Kyun Lee, Kyu Taek Lee, Yoon-La Choi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?